RNAi developer Protiva raises $3.3M
Protiva, a Vancouver, B.C.-based developer of drugs based on the new technology of RNA interference, raised $3.3 million in debenture financing. Investors included GrowthWorks Capital, BDC Capital, the Canadian Medical Discoveries Fund and Kinetic Capital.
Protiva is currently embroiled in litigation against two other biotechs, including Sirna Therapeutics, another RNAi company acquired by Merck last December, and Tekmira Pharmaceuticals.
U-Systems raises $16.5M for breast ultrasound systems
U-Systems, a San Jose, Calif., maker of ultrasound systems for breast imaging, raised $16.5 million in a fifth round of funding. The company, founded in 1997, markets its systems for the early detection of breast cancer, particularly in women with dense breast tissue.
Although based in Silicon Valley, the company has strong ties to Taiwan. Siemens Venture Capital led the round, joined by Sycamore Ventures, MDS Capital, Radius Ventures, Kinetic Capital, United Investments of Taiwan, President… Continue Reading